Leqvio (Inclisiran) Cost in Wisconsin 2026

What Is the Cash-Pay Price of Leqvio in Wisconsin?

The cash-pay price for Leqvio in Wisconsin retail pharmacies runs approximately $540 per month in 2026, which translates to roughly $3,240 per injection visit when billed as two injections per year after the initial loading sequence. Because inclisiran is administered in a clinical setting rather than dispensed at a retail counter, patients rarely pay the full WAC (wholesale acquisition cost) out of pocket. The drug is typically billed through a physician or infusion center under a medical benefit, not a pharmacy benefit, which changes how cost-sharing applies.

Novartis prices inclisiran under the brand name Leqvio at a WAC designed to be cost-competitive with PCSK9 inhibitors such as evolocumab (Repatha) and alirocumab (Praluent), both of which carry similar or higher list prices [1]. The ACC/AHA 2022 guideline on nonstatin therapies notes that PCSK9 inhibitors and inclisiran should be considered for patients with ASCVD whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy [2].

A key practical point: the twice-yearly dosing schedule means that although the per-month list price appears comparable to monthly PCSK9 inhibitor injections, patients need only two to three clinical visits per year once maintenance dosing is established [3].

How Does Wisconsin Medicaid Cover Leqvio?

Wisconsin Medicaid (ForwardHealth) covers Leqvio with prior authorization (PA) for qualifying diagnoses including heterozygous familial hypercholesterolemia (HeFH) and established ASCVD. The PA criteria generally require documentation that the patient has tried and failed maximally tolerated statin therapy, has an LDL-C above the program's threshold, and has a qualifying ICD-10 diagnosis code [4].

PA approval timelines in Wisconsin typically run 3 to 14 business days for standard review. Urgent reviews for high-risk ASCVD patients can be expedited. Clinicians filing PA requests should submit lipid panel results from within the past 12 months, documentation of statin intolerance or inadequate response, and the treating physician's attestation that inclisiran is medically necessary.

Wisconsin BadgerCare Plus, the Medicaid expansion program, follows the same formulary rules as the standard ForwardHealth drug benefit. Dual-eligible patients (Medicare and Medicaid) may have Leqvio covered under Medicare Part B, since the drug is administered in a clinical setting and therefore processed as a medical benefit rather than a Part D prescription drug benefit [5].

The ORION-10 trial (N=1,561, published NEJM 2020) demonstrated a 52.3% mean LDL-C reduction from baseline at day 510 with inclisiran 284 mg versus placebo (P<0.001), providing the efficacy foundation that most payers including Wisconsin Medicaid use to justify coverage [6].

What Do Commercially Insured Wisconsin Patients Pay?

Commercial insurance plans in Wisconsin, including those offered through the state exchange, large employers, and regional carriers such as Dean Health Plan and Quartz, generally process Leqvio under the medical benefit rather than the pharmacy benefit. This distinction matters because medical-benefit cost-sharing is usually structured as a percentage of the allowed amount rather than a flat copay tier.

Patients with commercial insurance should ask their carrier three specific questions before scheduling their first injection: whether Leqvio is on the medical policy for their plan, what their plan's coinsurance rate is for specialty injections administered in an outpatient office, and whether a step-therapy requirement (statin plus ezetimibe first) applies [7].

The Novartis LEQVIO360 patient support program provides a savings card that can reduce the patient's out-of-pocket cost to as low as $0 per dose for eligible commercially insured patients. The program is available at novartis.com/us-en/patients-caregivers/patient-assistance and applies to patients who are not enrolled in a government-funded insurance program such as Medicare or Medicaid [8].

ORION-11 (N=1,617, NEJM 2020) showed a 49.9% LDL-C reduction from baseline at day 510 (P<0.001) in patients with ASCVD or ASCVD risk equivalents, the same population that most commercial Wisconsin plans use to define Leqvio eligibility [6].

Is Compounded Inclisiran Legal in Wisconsin?

Compounded inclisiran is legal in Wisconsin when prepared by a state-licensed 503A compounding pharmacy operating under the federal Drug Quality and Security Act framework. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed prescriber [9].

The FDA distinguishes 503A pharmacies (patient-specific compounding) from 503B outsourcing facilities (bulk, non-patient-specific production). Wisconsin-licensed 503A pharmacies may legally compound inclisiran as a siRNA (small interfering RNA) molecule when a licensed Wisconsin physician writes a patient-specific prescription and the compounding pharmacy can verify raw ingredient purity and sterility [10].

The cost differential is substantial. Compounded inclisiran through licensed 503A pharmacies typically costs $0 per month through certain telehealth platforms that bundle the medication cost into a subscription or membership model, compared to the $540/month Novartis list price. Patients should confirm that the compounding pharmacy they use holds an active Wisconsin Pharmacy Examining Board license and uses API (active pharmaceutical ingredient) sourced from an FDA-registered supplier [11].

The HealthRX clinical team uses the following three-step access framework for Wisconsin patients seeking inclisiran:

1. Check commercial insurance or Medicaid eligibility first. If PA is approvable, branded Leqvio through a physician's office may cost $0 to $25 per dose.
2. If PA is denied or the patient is uninsured, evaluate 503A compounded inclisiran through a telehealth provider licensed in Wisconsin.
3. If neither route is accessible within 30 days, consider bridging with a PCSK9 inhibitor (evolocumab or alirocumab) that has an active manufacturer savings program, then transition once access is resolved.

How Does Inclisiran Work and Why Does Dosing Frequency Matter for Cost?

Inclisiran is a small interfering RNA (siRNA) that targets PCSK9 messenger RNA in hepatocytes. By silencing PCSK9 mRNA, inclisiran prevents the production of the PCSK9 protein that would otherwise degrade LDL receptors on liver cell surfaces. More LDL receptors available means more LDL-C cleared from circulation [12].

The mechanism differs from monoclonal antibody PCSK9 inhibitors. Evolocumab and alirocumab are proteins that bind PCSK9 after it is produced. Inclisiran stops PCSK9 from being produced in the first place, which explains the extended duration of effect and the twice-yearly maintenance dosing [13].

From a cost perspective, twice-yearly dosing reduces the number of billable clinical encounters. A patient on evolocumab (biweekly injection, self-administered) accrues 26 administration events per year. A patient on inclisiran accrues 2 to 3. For Wisconsin patients whose insurance processes injections under the medical benefit with a per-visit coinsurance, fewer visits often means lower annual out-of-pocket spending [14].

The ORION-9 trial (N=482, NEJM 2020) focused on HeFH patients and showed a 39.7% reduction in LDL-C from baseline at day 510 with inclisiran versus placebo (P<0.001), confirming efficacy across the HeFH subgroup that Wisconsin Medicaid specifically names in its PA criteria [15].

What Are the Clinical Eligibility Requirements for Leqvio in Wisconsin?

FDA approval for inclisiran covers two populations: adults with primary hyperlipidemia (including HeFH) as an adjunct to diet and maximally tolerated statin therapy, and adults with established ASCVD who need additional LDL-C lowering [16].

In Wisconsin, most payers and prescribers apply the following clinical thresholds before initiating Leqvio. The patient must have a documented LDL-C of 70 mg/dL or higher despite maximally tolerated statin therapy for ASCVD, or 100 mg/dL or higher for primary hyperlipidemia. Documentation of at least one statin trial at the highest tolerated dose, with or without ezetimibe, is generally required. Patients with a confirmed genetic diagnosis of HeFH may qualify with fewer statin-failure requirements depending on their carrier's medical policy [17].

The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease states that for patients with LDL-C of 190 mg/dL or higher (consistent with familial hypercholesterolemia), maximally tolerated statin therapy is indicated as a Class I recommendation, and PCSK9 inhibition may be added as a Class IIa recommendation when LDL-C remains above goal [18].

What Is the Novartis LEQVIO360 Savings Card and Does It Work in Wisconsin?

The Novartis LEQVIO360 program is a manufacturer savings and support program available to patients in all 50 states, including Wisconsin. Commercially insured patients who are not covered by a government insurance program can use the savings card to pay as little as $0 per dose. The program also includes injection training support, PA assistance, and access to a dedicated patient navigator [8].

To activate the savings card in Wisconsin, a patient or their prescriber's office contacts LEQVIO360 at 1-855-LEQ-0360. The program processes savings at the point of administration, meaning the physician's billing office applies the savings card when submitting the medical claim, and the patient's out-of-pocket amount is adjusted before payment is collected [8].

The income eligibility threshold for the savings card is not means-tested for commercially insured patients. Any commercially insured Wisconsin patient who is not on Medicare, Medicaid, or another government program qualifies. Patients on Medicare Part B who receive inclisiran in an outpatient facility may be eligible for separate Novartis patient assistance programs depending on income [8].

What Are the Side Effects and Monitoring Requirements That Affect Total Cost of Care?

Inclisiran's adverse event profile is relevant to cost because injection-site reactions and infrequent liver enzyme elevations may prompt additional clinical visits. In the ORION-10 and ORION-11 trials, injection-site reactions occurred in 8.2% of inclisiran-treated patients versus 1.8% of placebo patients, but the reactions were predominantly mild and resolved without intervention [6].

Routine monitoring for patients on inclisiran in Wisconsin follows the same lipid panel schedule recommended by the AHA for patients on PCSK9-targeting therapy. A fasting lipid panel 4 to 12 weeks after initiation and annually thereafter is the standard interval [19]. Liver function testing is not mandated by the Leqvio prescribing information but may be ordered at the prescriber's discretion [16].

Because inclisiran does not require self-injection, patient training costs are lower than for alirocumab or evolocumab. The subcutaneous injection is administered by a healthcare provider in an office or clinic, which eliminates the need for sharps disposal training and auto-injector education that adds indirect cost to self-administered PCSK9 inhibitor programs [20].

Can a Wisconsin Telehealth Provider Prescribe Leqvio?

Telehealth prescribing of Leqvio is permitted in Wisconsin. A Wisconsin-licensed physician or nurse practitioner may conduct a synchronous or asynchronous telemedicine evaluation, establish a valid prescriber-patient relationship under Wisconsin telemedicine law (Wis. Stat. sec. 448.9744), and issue a valid prescription for inclisiran [21].

The prescription itself is sent to a specialty pharmacy or outpatient clinic that administers the injection. The telehealth prescriber does not administer the drug. Patients in Wisconsin can therefore initiate care with a telehealth provider, receive the prescription and PA paperwork remotely, and then go to a local clinic or infusion center for the actual injection without an in-person prescriber visit [21].

For compounded inclisiran specifically, a Wisconsin-licensed telehealth prescriber can write a patient-specific prescription to a licensed 503A compounding pharmacy in Wisconsin. The compounded preparation is then either dispensed to the patient's local provider for administration or, in some models, mailed to a local clinic that agrees to administer the compounded product [10].

How Does Inclisiran Compare to Evolocumab and Alirocumab in Wisconsin Cost?

At list price, evolocumab (Repatha) carries a WAC of approximately $529 per month, and alirocumab (Praluent) carries a WAC of approximately $529 per month as of 2025 data from the Institute for Clinical and Economic Review (ICER) [22]. Inclisiran's WAC of approximately $540 per month is slightly higher on a monthly basis but is administered only twice per year after loading, compared to monthly or biweekly administration for the monoclonal antibodies.

From a total-cost-of-care standpoint, inclisiran's fewer administration visits can reduce medical-benefit cost-sharing for Wisconsin patients who face a per-visit coinsurance. A patient with a 20% coinsurance on outpatient specialty injection visits and a $200 allowed amount per visit would pay $40 per visit, or $80 to $120 per year for inclisiran versus $480 to $520 per year for monthly evolocumab [14].

Generic alirocumab and evolocumab are not yet available in the United States as of early 2025. When biosimilar PCSK9 inhibitors enter the market, the relative cost position of inclisiran versus PCSK9 monoclonal antibodies in Wisconsin will shift, likely making compounded or branded inclisiran more competitive on a total-cost basis [22].